Summary
Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Decline
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes: Idiopathic Hypersomnia Could Expand Lumryz Into A Larger Growth And Margin Driver
Alkermes is positioned for significant growth through LUMRYZ's potential expansion into idiopathic hypersomnia (IH), following positive Phase 3 results. LUMRYZ's IH indication could drive incremental revenue, leveraging existing commercial infrastructure and delivering operating leverage with a limited SG&A increase. ALKS faces a 10% royalty to Jazz Pharmaceuticals on non-narcolepsy LUMRYZ sales post-March 2028, but the opportunity remains financially meaningful.
Alkermes: A Slow-Burning Buy Prospect On Orexin-Agonist Promise
Alkermes plc is upgraded from Hold to Buy, driven by robust revenue growth, pipeline momentum, and strategic positioning in sleep and CNS disorders. Acquisition of Avadel and Lumryz launch propel >20% revenue growth in 2026; adjusted EBITDA guidance is $370–410M despite a GAAP net loss. Alixorexton's strong Phase 2 data in narcolepsy and IH, plus advancing orexin pipeline, underpin multi-billion-dollar long-term revenue potential.
Alkermes plc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 153 | $5,884.24 | $6,655.5 | $771.26 | 13.11% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 100 | $2,798 | $4,425.13 | $1,627.13 | 58.15% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 48 | $2,206.91 | $2,079.84 | -$127.07 | -5.76% |
| NA Nizar Araji National Bank Of Canada /FI/ | 7,464 | $247,685.24 | $324,684 | $76,998.76 | 31.09% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 750 | $25,727.61 | $32,610 | $6,882.39 | 26.75% |
Alkermes plc (ALKS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Alkermes plc ever had a stock split?
Alkermes plc Profile
| Biotechnology Industry | Healthcare Sector | Blair Jackson CEO | NASDAQ (NGS) Exchange | G01767105 CUSIP |
| IE Country | 2,050 Employees | - Last Dividend | 15 May 2000 Last Split | 16 Jul 1991 IPO Date |
Overview
Alkermes plc stands out as a pivotal player in the biopharmaceutical sector, dedicated to discovering, developing, and commercializing innovative pharmaceutical solutions aimed at fulfilling the unmet medical necessities of patients. The company's operations span across the United States, Ireland, and other global territories, focusing on significant therapeutic areas. Founded in 1987, with its headquarters located in Dublin, Ireland, Alkermes plc has carved a niche for itself by concentrating on the treatment of alcohol and opioid dependencies, schizophrenia, and bipolar I disorder. Through its dynamic portfolio of proprietary commercial products and a robust pipeline of clinical and preclinical candidates, Alkermes plc endeavors to transform the therapeutic landscape of neurological disorders. Moreover, the company fosters strategic collaboration agreements with prestigious entities such as Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International, leveraging its proprietary technology platforms to assist third parties in developing, commercializing, and manufacturing their products.
Products and Services
- ARISTADA: An innovative intramuscular injectable suspension, ARISTADA is meticulously designed for the treatment of schizophrenia. It represents a cornerstone in Alkermes plc’s portfolio, offering sustained relief and management of symptoms associated with this complex mental health condition.
- ARISTADA INITIO: Tailored for adults diagnosed with schizophrenia, ARISTADA INITIO embodies an enhanced treatment solution to initiate and stabilize patients. This formulation underscores Alkermes plc's commitment to advancing psychiatric care and improving patient outcomes through targeted therapy.
- VIVITROL: Manifesting a pioneering approach to overcoming alcohol and opioid dependence, VIVITROL is an extended-release, injectable medication. Its mechanism of action provides a non-addictive treatment pathway, significantly contributing to the prevention of relapse in individuals striving for recovery.
- LYBALVI: Emerging as a groundbreaking oral atypical antipsychotic candidate, LYBALVI is intended for the treatment of adults suffering from schizophrenia and bipolar I disorder. This promising product candidate exemplifies Alkermes plc’s relentless drive towards introducing novel therapies that encapsulate both safety and efficacy.
Contact Information
